Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. - Wikidata - wikimedia - TriplyDB

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

http://www.wikidata.org/entity/Q40211560

about

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.Physiology, injury, and recovery of interstitial cells of Cajal: basic and clinical science Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.New fronts in the adjuvant treatment of GIST.Gastrointestinal stromal tumor - an evolving concept.The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells Emerging drugs for the treatment of soft tissue sarcomas.The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.Clinical implications of mutational analysis in gastrointestinal stromal tumours.Clinical applications of metabolomics in oncology: a review.New therapeutic approaches for advanced gastrointestinal stromal tumors.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Crenolanib is a selective type I pan-FLT3 inhibitor Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Nilotinib: a novel, selective tyrosine kinase inhibitor.Metabolomics in urogenital cancer.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.Gastrointestinal stromal tumors: what do we know now?Current clinical strategy for imatinib-resistant gastrointestinal stromal tumors.The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.Nilotinib for the treatment of chronic myeloid leukemia.NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor.Relationship between gene mutations and protein expressions of PDGFR α and C-kit in gastrointestinal stromal tumors.A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature.Midostaurin: a magic bullet that blocks mast cell expansion and activation.Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.

P2860

Q27660281-80BDEB5C-B487-4ABB-B010-E748ED12EC7D Q33392955-86BB327E-DE4C-4F77-BB2C-B135234DD491 Q33654894-CF8295A6-C3C6-48D9-88CF-7BF8A3F43732 Q34145366-319DE40A-4859-4C36-B44E-B1B659908634 Q34499075-FD3230A4-6CC3-4BDD-8BDB-A30B4AAD4CA0 Q34655266-67A82FB0-A802-46A6-96F2-D9676160559D Q34928165-60A6BB15-A0E6-4952-9F66-CC9D3E7B0CE0 Q35018563-3E97EA63-6375-45F4-8577-61651A89D038 Q35252470-5ECE7E7E-81AA-4AB0-A8CB-2662A684B881 Q36758596-6C69B412-7803-467D-B97D-6EEA83CF025E Q36964732-3DA2B395-1D97-4056-9526-32FBB994D16B Q37078090-4FDE31C7-983A-4531-92B5-95EB8EDBFEA5 Q37177549-5F6A2243-294D-404D-A516-7ACEB49F62D3 Q37403036-FF2B4AF4-058D-4D27-8B43-98DE79E4FA61 Q37598944-B5D3FFBE-F2EB-4294-9A1D-E985F99C9614 Q37701978-643E64F3-6545-4DF8-846C-81FC6B40C694 Q37823438-86D9771B-4743-4EF7-B719-7343511C7646 Q37855073-7207DF65-D5E5-42FA-BD0B-B2ADB2F2C868 Q37867682-1786AB2A-74B4-4229-BC0B-0A911BDC424A Q38112821-8B773A70-D33A-4BE0-BC8C-69AA1072AB58 Q38151827-9260974E-85D8-47CD-AE2A-A0036B91D95A Q38175310-8DE5B471-6C3E-455B-B210-016FEF9B7F98 Q38550665-19037CC0-9ADC-4958-AD2C-8ACD2647C419 Q39640407-F17CD575-C302-4542-9307-37DB2D966955 Q40041737-FED865B3-CFFA-4452-B795-6546E023E3F6 Q40401088-15EC9094-7D50-41EC-9E6A-1578691A327D Q41691560-788A3347-815C-432D-A54D-5D554AB8DA63 Q41846953-6C4F3DCD-944F-45A7-95DD-4FA7AF0FF0AE Q43248374-32DDEBD4-77E8-469A-B8CC-46F05998F443 Q47191981-EC41E02B-2C6C-42C1-82F9-F6F824992963 Q47930594-5F6AB3BE-C1C5-46E4-BE6F-503B2CA6E191 Q54365521-8C45D8ED-0363-427C-A12E-750393FF61FF Q54402485-43C0282F-9BF9-4F39-AE9C-1B1AD94E9E2D Q55362356-618D1B53-88E9-4C6F-8D96-48A4E78ED561

P2860

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

http://www.wikidata.org/entity/Q40211560

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Effects of PKC412, nilotinib, ...... erential imatinib sensitivity.

@en

type

label

Effects of PKC412, nilotinib, ...... erential imatinib sensitivity.

@en

prefLabel

Effects of PKC412, nilotinib, ...... erential imatinib sensitivity.

@en

P1433

Q40211560-54C93465-2AB2-46C8-8E6C-B410BE3BD43B

P1476

Q40211560-944839B8-E0C0-44F1-87A9-5C0650E7DD20

P2093

Q40211560-483B98B9-68EC-4A51-81BE-1879DC936B22

Q40211560-601D9770-F9DB-410C-8E6A-B299F7897343

Q40211560-632C6384-1B3A-47BB-831B-942782ECD62C

Q40211560-67310E80-4077-4A66-B169-FB576A386C30

Q40211560-675026F9-F076-4189-B5E2-4F3579CB635A

Q40211560-833B0DCA-F82C-4DE3-9C4A-322DEC22AB19

Q40211560-A43EC294-9C38-4651-AD8E-0CFF6BB39ACB

Q40211560-B8CC6C18-9563-4884-892A-C8F5E09C8746

Q40211560-C60930F4-C93D-4079-82F5-245336EC5DFB

Q40211560-CDB6D229-E612-4575-B5C8-B0CC8D0D68B3

P2860

Q40211560-0E0F9ED5-CB16-4956-AF46-AC0CB4D217A5

Q40211560-25A52F98-0626-4EA3-90C9-C4FEDA74FE9B

Q40211560-3742E1DE-FD43-4528-A7A2-CD490BC8C3F8

Q40211560-4F4003D4-0DCC-4FCE-9C42-4A6D62724A92

Q40211560-52583098-255C-4942-85B7-44A36D01D76C

Q40211560-6ADB3DE1-C02B-47AF-A61D-8B7B7F369798

Q40211560-6C20B9EF-5FF2-4CD7-9B9B-3C5FBBFD9569

Q40211560-7184DBB9-8205-4525-B206-CA66D119AE65

Q40211560-79F3639A-954F-4B7A-9B1E-BF3E849D9199

Q40211560-83D7CC5D-651A-4E1A-ABFF-651D45F0CAFC

P304

Q40211560-ECD03653-9D27-40EF-AA37-FF4F1AFB902A

P31

Q40211560-A661A073-E554-4CD2-A9DD-F19EDB3481B9

P356

Q40211560-3AB673C9-3690-487C-8AA8-FE4157C287BA

P407

Q40211560-E0EC0566-2673-4C72-BB2E-E237FC700C27

P433

Q40211560-49301459-C7F2-4E13-A8DA-514987EA6001

P478

Q40211560-0823D6EC-C8B8-4758-B151-8714C1498F53

P50

Q40211560-9455299A-0F28-437A-BCF9-CAFBD1004367

P577

Q40211560-BDEB5BFC-6BCE-4F5C-B783-3EC1078B7EB0

P5875

Q40211560-A1EFDBC4-9B5F-4D0E-8346-46699796D1F5

P698

Q40211560-13CBAD44-BA1F-49AC-8F5F-0B3BF60FBC08

P932

Q40211560-512B2EA0-45E2-4D3C-BDAC-9FD8EF02C357

P356

J.GASTRO.2006.09.017

P1433

Gastroenterology

P1476

Effects of PKC412, nilotinib, ...... erential imatinib sensitivity.

@en

P2093

Arghya Ray

http://www.w3.org/2001/XMLSchema#string

Daisy Moreno

http://www.w3.org/2001/XMLSchema#string

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hall-Meyers

http://www.w3.org/2001/XMLSchema#string

Ellen Weisberg

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Jingrui Jiang

http://www.w3.org/2001/XMLSchema#string

Klaus Podar

http://www.w3.org/2001/XMLSchema#string

Laurie Catley

http://www.w3.org/2001/XMLSchema#string

Paul W Manley

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

PDGFRA activating mutations in gastrointestinal stromal tumors.

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

P304

1734-1742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2006.09.017

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6709068

http://www.w3.org/2001/XMLSchema#string

P698

17087936

http://www.w3.org/2001/XMLSchema#string

P932

2967439

http://www.w3.org/2001/XMLSchema#string